Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women-Reference-Cited by-同舟云学术

Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

Published:2003-11 Issue:16 Volume:39 Page:2310-2317
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Thürlimann B.,Robertson J.F.R.,Nabholtz J.M.,Buzdar A.,Bonneterre J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Tamoxifen for early breast cancer;Lancet,1998

2. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma;Buzdar;Cancer,1998

3. Letrozole, a new oral aromatase inhibitor for advanced breast cancer;Dombernowsky;J. Clin. Oncol.,1998

4. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women—results of the TARGET (Tamoxifen or Arimidex™ Randomised Group Efficacy and Tolerability) study;Bonneterre;J. Clin. Oncol.,2000

5. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women;Nabholtz;J. Clin. Oncol.,2000

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs;Scientific Reports;2024-06-11

2. Oral low-dose cyclophosphamide with endocrine therapy through effects on Tregs in TLSs may improve clinical response in elderly metastatic breast cancer patients;2023-12-04

3. Brief Overview of Breast Cancer Treatment;A Practical Guide to Breast Cancer Treatment;2023

4. Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer;Cancers;2022-09-01

5. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer;European Journal of Cancer;2021-03